Status:
UNKNOWN
Evaluation of Intraoperative Slow-release Dexamethasone Implant for Epiretinal Membrane
Lead Sponsor:
Peking University People's Hospital
Conditions:
Epiretinal Membrane
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Epiretinal membrane (ERM) is a commonly encountered vitreoretinal interface anomaly with a prevalence of approximately 10% in the adult population. It is often treated with pars plana vitrectomy (PPV)...
Detailed Description
Small gauge pars plana vitrectomy (PPV) with membrane peeling is used to successfully treat macular epiretinal membranes (ERMs) with a postoperative improvement of visual acuity in the majority of cas...
Eligibility Criteria
Inclusion
- patients with a visually significant (BCVA\<20/50) idiopathic epiretinal membrane.
- ocular axial length less than 27.00 mm (optical biometry) associated with cataracts.
Exclusion
- concomitant or previous macular diseases (diabetic macular edema, retinal vein occlusion and agerelated macular degeneration).
- secondary epiretinal membrane, other visually significant macular pathology and prior intravitreal triamcinolone acetonide injection.
Key Trial Info
Start Date :
June 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05416827
Start Date
June 15 2022
End Date
September 15 2022
Last Update
June 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.